Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
- PMID: 19759533
- PMCID: PMC3172006
- DOI: 10.1038/nature08463
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
Abstract
Hepatitis C virus (HCV) infection is the most common blood-borne infection in the United States, with estimates of 4 million HCV-infected individuals in the United States and 170 million worldwide. Most (70-80%) HCV infections persist and about 30% of individuals with persistent infection develop chronic liver disease, including cirrhosis and hepatocellular carcinoma. Epidemiological, viral and host factors have been associated with the differences in HCV clearance or persistence, and studies have demonstrated that a strong host immune response against HCV favours viral clearance. Thus, variation in genes involved in the immune response may contribute to the ability to clear the virus. In a recent genome-wide association study, a single nucleotide polymorphism (rs12979860) 3 kilobases upstream of the IL28B gene, which encodes the type III interferon IFN-3, was shown to associate strongly with more than a twofold difference in response to HCV drug treatment. To determine the potential effect of rs12979860 variation on outcome to HCV infection in a natural history setting, we genotyped this variant in HCV cohorts comprised of individuals who spontaneously cleared the virus (n = 388) or had persistent infection (n = 620). We show that the C/C genotype strongly enhances resolution of HCV infection among individuals of both European and African ancestry. To our knowledge, this is the strongest and most significant genetic effect associated with natural clearance of HCV, and these results implicate a primary role for IL28B in resolution of HCV infection.
Conflict of interest statement
The authors declare no competing financial interests.
Figures


References
-
- Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47(RR-19):1–39. - PubMed
-
- Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46. - PubMed
-
- Cooper S, et al. Analysis of a successful immune response against hepatitis C virus. Immunity. 1999;10(4):439–449. - PubMed
-
- Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5 (3):215–229. - PubMed
-
- Ge D, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 In Press. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R56 DA004334/DA/NIDA NIH HHS/United States
- R01 DK060590/DK/NIDDK NIH HHS/United States
- R01 DA013324/DA/NIDA NIH HHS/United States
- R01DA013324/DA/NIDA NIH HHS/United States
- R01 HL076902/HL/NHLBI NIH HHS/United States
- R01 HD041224/HD/NICHD NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- R01DK60590/DK/NIDDK NIH HHS/United States
- HHSN261200800001C/RC/CCR NIH HHS/United States
- HHSN261200800001E/CA/NCI NIH HHS/United States
- R01HL076902/HL/NHLBI NIH HHS/United States
- R01 DA004334/DA/NIDA NIH HHS/United States
- R01HD41224/HD/NICHD NIH HHS/United States
- R01 DA012568/DA/NIDA NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- R01DA004334/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical